GSK-3 inhibitors

摘要

Disclosed is the use of a aryl amide of formula (I) or any pharmaceutically acceptable salt, prodrug or solvate thereof wherein RB is selected from alkyl, cycloalkyl, substituted aryl, R3, R4, R'2, R'3, R'4, R'5, R'6 as defined in the specification in the manufacture of a medicament for the treatment and/or prevention of a GSK-3 mediated disease or condition wherein the disease or condition is selected from the group of diabetes, conditions associated with diabetes, chronic neurodegenerative conditions including dementias such as Alzheimer's disease, Parkinson's disease, progressive supranuclear palsy, subacute sclerosing panencephalitic parkinsonism, postencephalitic parkinsonism, pugilistic encephalitis, guam parkinsonism-dementia complex, Pick's disease, corticobasal degeneration, frontotemporal dementia, Huntington's Disease, AIDS associated dementia, amyotrophic lateral sclerosis, multiple sclerosis and neurotraumatic diseases such as acute stroke, epilepsy, mood disorders such as depression, schizophrenia and bipolar disorders, promotion of functional recovery post stroke, cerebral bleeding such as due to solitary cerebral amyloid angiopathy, hair loss, obesity, hypertension, polycystic ovary syndrome, syndrome X, ischaemia, brain injury, traumatic brain injury, cancer, leukopenia, Down's syndrome, Lewy body disease, inflammation, chronic inflammatory diseases, cancer and hyperproliferative diseases as hyperplasias and immunodeficiency. Also disclosed is the specific compound 1-benzo[1,3]dioxol-5-yl-3-benzyl-urea and compositions comprising this compound.